Article info
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
739 A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
Citation
739 A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
Publication history
- First published November 7, 2022.
Online issue publication
April 26, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.